Endo Pharma, Orion Corp. to Advance Cancer Drugs

(USTR.gov)

Endo Pharmaceuticals in Chadds Ford, Pennsylvania and Orion Corporation in Espoo, Finland said today they have a collaboration agreement for drug research and development in oncology.

The partnership aims to advance eight discovery-phase cancer drug candidates by combining their relevant R&D programs. The collaboration also gives each company exclusive licensing rights to the other’s development-ready programs at agreed-upon stages and to share all development costs.

Endo Pharmaceuticals, a specialty health care company, offers a variety of generic and branded drug products. Orion Corp. provides medicinal treatments and diagnostic tests, including drugs for central nervous system, cancer, and pulmonary conditions.

Read more: Spirogen, Genentech Partner on Anti-Cancer Therapies

*     *     *